RMB 790 million! Jiuzhou pharmaceutical intends to acquire Suzhou Novartis
-
Last Update: 2019-09-05
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
On September 4, 2019, Zhejiang Jiuzhou Pharmaceutical Co., Ltd issued a notice that in order to further expand cdmo projects, develop new products and bring rapid business growth, the company plans to cooperate with Novartis international pharmaceutical investment Ltd (Novartis international pharmaceutical investment Co., Ltd.) signed the equity acquisition agreement, and plans to purchase 100% equity of Suzhou Novartis after divestiture of technology and drug development assets held by Novartis investment with self raised capital of about RMB 790 million After the completion of this transaction, Suzhou Novartis will become a wholly-owned subsidiary of Jiuzhou pharmaceutical The following is the original announcement: statement: This article is the reprinted content of yaozhi.com, and the copyright belongs to the original author The purpose of reprinting is to transmit more information, and does not represent the view of this platform If the content, copyright and other issues of the work are involved, please contact the message on this website, and we will delete the content as soon as possible
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
